在心力衰竭中可溶性ST2:超越B型天然尿素的临床作用
Mauro Riccardi1, Peder L Myhre2,3, Thomas A Zelniker4
1Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, 25121 Brescia, Italy.
Journal of cardiovascular development and disease
|November 24, 2023
概括
溶性ST2 (sST2) 是心力衰竭的生物标志物,不受常见因素的影响,与尿酸不同. 将sST2与NP结合使用可能会改善心力衰竭患者的治疗.
科学领域:
- 心脏病学 心脏病学
- 生物标志物研究 生物标志物研究
- 心脏衰竭管理的管理
背景情况:
- 溶性ST2 (sST2) 是一种涉及心力衰竭 (HF) 管理的生物标志物.
- 肌动脉损伤或压力刺激sST2释放,可能导致纤维化和重塑.
- 与天然尿素 (NP) 不同,sST2水平受到人口和临床因素的影响很小,显示出较低的个体内变化.
研究的目的:
- 审查关于急性和慢性HF的sST2的当前知识.
- 突出 sST2 与 HF 管理的 NP 结合的潜在添加作用.
主要方法:
- 关于sST2.2的科学知识的文献综述.
- 专注于sST2在急性和慢性心力衰竭中的作用.
- 分析sST2的添加值与天然尿素.
主要成果:
- sST2 是高频率的独立预后标志物.
- 与NP相比,sST2受到混因素的影响较小.
- 由于不同的生物途径,sST2和NP的组合可能会带来好处.
结论:
- sST2显示出作为HF管理的生物标志物具有前途.
- 将sST2与NP结合使用可能会提高预后准确性和治疗指导.
- 需要进一步的研究,以制定在高频中联合使用sST2和NP的指导方针.
相关概念视频
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
97
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
97
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Heart Failure Drugs: Diuretics
398
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
398
Heart Failure Drugs: β-Blockers
344
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
344
Heart Failure Drugs: Inotropic Agents
596
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
596
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K


